Validation studies across a heterogeneous panel of patient-derived GBM stem cells demonstrated potent FAK+MEK inhibitor combination activity at nanomolar concentrations in 2D and 3D phenotypic assays and reduced tumor area in an in vivo orthotopic transplantation model. This evidence concerns the gene PTK2 and glioblastoma.